Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
biotech · Type 1 Diabetes Mellitus · Dehydration · HALO
HALOZYME THERAPEUTICS
HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 12390 El Camino Real, San Diego, California 92130, US
- Founded
- 2021
- Employees
- 530
- Programs
- 45
- Drugs
- 33
- Patents
- 70
HALOZYME THERAPEUTICS pipeline
Portfolio lens on 33 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
HALOZYME THERAPEUTICS drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
c1 inhibitor (human)
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in HALOZYME THERAPEUTICS's portfolio. Molecular target: Coagulation factor XI.
- Target
- Coagulation factor XI
- Mechanism
- Coagulation factor XI inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HALOZYME THERAPEUTICS's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in HALOZYME THERAPEUTICS's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
US regulatory status: approved. Molecular target: Hyaluronic acid.
- Target
- Hyaluronic acid
- Mechanism
- Hyaluronic acid hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Hyaluronic acid.
- Target
- Hyaluronic acid
- Mechanism
- Hyaluronic acid hydrolytic enzyme
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin lispro
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
US regulatory status: approved. Mechanism: Adrenergic receptor alpha agonist.
- Mechanism
- Adrenergic receptor alpha agonist
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.
-
testosterone
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor agonist
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor agonist
-
Development asset linked to HALOZYME THERAPEUTICS in public FDA and regional records.